{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:34:51Z","timestamp":1792787691245,"version":"4.5.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100017262","name":"Instituto de Investigaciones en Microbiolog\u00eda, Universidad Nacional Autonoma de Honduras","doi-asserted-by":"publisher","award":["2-03-01-01"],"award-info":[{"award-number":["2-03-01-01"]}],"id":[{"id":"10.13039\/501100017262","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Global Communities","id":[{"id":"https:\/\/ror.org\/04rqj7157","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Global Fund"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Health Educ Behav"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Comprehensive care services (SAIs) play a pivotal role in implementing preventive strategies by offering treatments that have demonstrated efficacy, as exemplified by dolutegravir (DTG). This medication has been employed in various clinical settings because of its pronounced genetic barrier and high tolerance. To characterize the clinical and epidemiological use of dolutegravir in people living with HIV (PLHIV) treated for SAI in Honduras. Cross-sectional studies and secondary analyses of the 2020 to 2021 phenotypic database were performed with SPSS (version 20.0). Ethics Committee approval (057-2021). Out of 2,984 records with sociodemographic data, 44% were women, and 56% were men. The population included 2,221 general population patients, 684 men who have sex with men (MSM), 185 Garifuna, 36 trans women, 8 bisexuals, 6 pregnant women, and 2 prisoners. The average age was 39.5 years. First-line ARVs are the most commonly used type of SAI. The National Cardiopulmonary Institute was the center with the highest use of dolutegravir, with 37.7% of patients receiving it. Among the 3,533 antiretroviral therapy (ART) patient records, 80.1% achieved complete viral suppression (viral load &lt;1,000 copies), with a 95% confidence interval of 78.7%-81.3%. High viral loads were observed in PLHIV receiving ART, regardless of the population type. Monitoring of antiretroviral resistance through phenotypic and genotypic testing is crucial for optimizing HIV treatment in Honduras.<\/jats:p>","DOI":"10.1177\/10901981251411221","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T15:45:36Z","timestamp":1769874336000},"page":"487-495","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Epidemiological Profile of Dolutegravir Use and Antiretroviral Resistance in Honduras"],"prefix":"10.1177","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-2276","authenticated-orcid":false,"given":"Itzel C.","family":"Fuentes-Barahona","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences (FCM), National Autonomous University of Honduras, Tegucigalpa, Honduras"},{"name":"Group GRINVAR, Faculty of Medical Sciences (FCM), National Autonomous University of Honduras (UNAH). Tegucigalpa, Honduras"},{"name":"Teaching Hospital, Tegucigalpa, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7218-3481","authenticated-orcid":false,"given":"Eleonora","family":"Espinoza-Turcios","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences (FCM), National Autonomous University of Honduras, Tegucigalpa, Honduras"},{"name":"Group GRINVAR, Faculty of Medical Sciences (FCM), National Autonomous University of Honduras (UNAH). Tegucigalpa, Honduras"},{"name":"Group of Mental Health, Faculty of Medical Sciences (FCM), National Autonomous University of Honduras (UNAH). Tegucigalpa, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7679-6602","authenticated-orcid":false,"given":"Henry Noel","family":"Castro-Ramos","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences (FCM), National Autonomous University of Honduras, Tegucigalpa, Honduras"},{"name":"Group GRINVAR, Faculty of Medical Sciences (FCM), National Autonomous University of Honduras (UNAH). Tegucigalpa, Honduras"},{"name":"Group of Mental Health, Faculty of Medical Sciences (FCM), National Autonomous University of Honduras (UNAH). Tegucigalpa, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8128-8602","authenticated-orcid":false,"given":"Iveth","family":"Lorenzana de Rivera","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences (FCM), National Autonomous University of Honduras, Tegucigalpa, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1221-0518","authenticated-orcid":false,"given":"Fausto","family":"Mu\u00f1oz-Lara","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences (FCM), National Autonomous University of Honduras, Tegucigalpa, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-8735","authenticated-orcid":false,"given":"Manuel","family":"Sierra","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences (FCM), National Autonomous University of Honduras, Tegucigalpa, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4976-0716","authenticated-orcid":false,"given":"Roberta","family":"L. Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Federal University of Amazonas, Manaus, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1612-5529","authenticated-orcid":false,"given":"Mario","family":"Cooper","sequence":"additional","affiliation":[{"name":"Global Communities CHF, Tegucigalpa, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4087","authenticated-orcid":false,"given":"Altay","family":"Lino de Souza","sequence":"additional","affiliation":[{"name":"Federal University of Sao Paulo, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Armada","sequence":"additional","affiliation":[{"name":"Continental University, Huancayo, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R. Mej\u00eda","sequence":"additional","affiliation":[{"name":"University of Peru Applied Sciences, Santiago de Surco, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-5807","authenticated-orcid":false,"given":"Lysien I.","family":"Zambrano","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences (FCM), National Autonomous University of Honduras, Tegucigalpa, Honduras"},{"name":"Group GRINVAR, Faculty of Medical Sciences (FCM), National Autonomous University of Honduras (UNAH). Tegucigalpa, Honduras"},{"name":"Group of Mental Health, Faculty of Medical Sciences (FCM), National Autonomous University of Honduras (UNAH). Tegucigalpa, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"crossref","unstructured":"Aguilar G. Truong H.-H. M. Ovelar P. Samudio T. Lopez G. Garc\u00eda-Morales C. Tapia-Trejo D. L\u00f3pez-S\u00e1nchez D. M. \u00c1vila-R\u00edos S. Giron A. De Arias A. R. Rios-Gonzalez C. McFarland W. (2022). HIV drug resistance in persons initiating or reinitiating first-line antiretroviral therapy in Paraguay: Results of a National Patient Survey. Journal of Medical Virology 94(10) 5061\u20135065. https:\/\/doi.org\/10.1002\/jmv.27933","DOI":"10.1002\/jmv.27933"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Alkhawaldeh A. ALBashtawy M. Rayan A. Abdalrahim A. Musa A. Eshah N. Abu Khait A. ALBashtawy S. (2023). Application and use of Andersen\u2019s behavioral model as theoretical framework: A systematic literature review from 2012-2021. Iranian Journal of Public Health 52(7) 1346\u20131354. https:\/\/doi.org\/10.18502\/ijph.v52i7.13236","DOI":"10.18502\/ijph.v52i7.13236"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Bowman C. Ambrose A. Kanitkar T. Flores K. Simoes P. Hart J. Hunter A. Akodu J. Barber T. J. (2023). Real world use of dolutegravir two drug regimens. AIDS 37(5) 785\u2013788. https:\/\/doi.org\/10.1097\/QAD.0000000000003480","DOI":"10.1097\/QAD.0000000000003480"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Cecchini D. Cassetti I. Scarnato F. Fiori A. Nuevo J. Villaverde C. Sucari A. Torroija M. C. Bissio E. Bugarin G. Lopardo G. (2025). Prevalence of Doravirine Resistance Mutations in a Large-Scale HIV-1 Transmitted Drug Resistance Survey in Buenos Aires Argentina. Viruses 17(5). https:\/\/doi.org\/10.3390\/v17050731","DOI":"10.3390\/v17050731"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Chandasana H. Bush M. Vavro C. Huang J. Ait-Khaled M. Wynne B. Min S. Mehta R. (2024). Integrated population exposure-response of dolutegravir in HIV-1 supports bridging of clinical response influenced by relevant intrinsic and extrinsic patient characteristics. Clinical Pharmacology and Therapeutics 116(4) 1100\u20131109. https:\/\/doi.org\/10.1002\/cpt.3370","DOI":"10.1002\/cpt.3370"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Cordova E. Hernandez Rendon J. Mingrone V. Martin P. Arevalo Calderon G. Seleme S. Ballivian J. Porteiro N. (2025). Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4 randomised open-label non-inferiority trial. The Lancet HIV 12(2) e95\u2013e104. https:\/\/doi.org\/10.1016\/S2352-3018(24)00294-7","DOI":"10.1016\/S2352-3018(24)00294-7"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Cruciani M. Parisi S. G. (2019). Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis. PLOS ONE 14(9) e0222229. https:\/\/doi.org\/10.1371\/journal.pone.0222229","DOI":"10.1371\/journal.pone.0222229"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Doblado-Maldonado A. Ooi A. Y. R. Cheng C.-Y. Sun W. Letang E. Moorhouse M. Jones B. (2025). Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review. Medicine 104(33) e43558. https:\/\/doi.org\/10.1097\/MD.0000000000043558","DOI":"10.1097\/MD.0000000000043558"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Doro Altan A. M. Majid N. Orlando S. Uamusse E. Rafael M. Sidumo Z. Guidotti G. Ciccacci F. (2025). Brief communication: Virological outcomes and dolutegravir resistance mutations in HIV-infected patients: A multicenter retrospective cohort study in Mozambique. AIDS Research and Therapy 22(1) 8. https:\/\/doi.org\/10.1186\/s12981-025-00708-w","DOI":"10.1186\/s12981-025-00708-w"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Figueroa M. I. [Maria Ines] Brites C. Cecchini D. Ramalho A. Francos J. L. Lacerda M. Rolon M. J. Madruga J. V. Sprinz E. Souza T. N. L. Parenti P. Converso D. Mernies G. Sued O. Cahn P. (2025). Efficacy and safety of dual therapy with dolutegravir\/lamivudine in treatment-naive persons with CD4 counts <200\/mm3: 48-week results of the DOLCE study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. Advance Online Publication. https:\/\/doi.org\/10.1093\/cid\/ciaf415","DOI":"10.2139\/ssrn.5151362"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Fonseca F. F. Ranadive P. Shepherd B. E. Ferreira F. G. F. Rodr\u00edguez M. F. Machado D. M. [Daisy M. ]. Rouzier V. Varela D. Maruri F. Ribeiro P. Grinsztejn B. Wagner Cardoso S. Veloso V. G. Castilho J. L. Jalil E. M. (2025). Persistent sex disparities in access to dolutegravir-based antiretroviral therapy in Latin America and the Caribbean: Results from a retrospective observational study using data from 2017 to 2022. Journal of the International AIDS Society 28(7) e26470. https:\/\/doi.org\/10.1002\/jia2.26470","DOI":"10.1002\/jia2.26470"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Frola C. E. Aristegui I. Figueroa M. I. [Mar\u00eda I. ]. Radusky P. D. Cardozo N. Zalazar V. Cesar C. Patterson P. Fink V. Gun A. Cahn P. Sued O. (2023). Retention among transgender women treated with dolutegravir associated with tenofovir\/lamivudine or emtricitabine in Argentina: TransViiV study. PLOS ONE 18(1) e0279996. https:\/\/doi.org\/10.1371\/journal.pone.0279996","DOI":"10.1371\/journal.pone.0279996"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Gandhi R. T. Landovitz R. J. Sax P. E. Smith D. M. Springer S. A. G\u00fcnthard H. F. Thompson M. A. Bedimo R. J. Benson C. A. Buchbinder S. P. Crabtree-Ramirez B. E. Del Rio C. Eaton E. F. Eron J. J. Hoy J. F. Lehmann C. Molina J.-M. Jacobsen D. M. Saag M. S. (2025). Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 Recommendations of the International Antiviral Society-USA Panel. Journal of the American Medical Association 333(7) 609\u2013628. https:\/\/doi.org\/10.1001\/jama.2024.24543","DOI":"10.1001\/jama.2024.24543"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Inzaule S. C. Hamers R. L. Doherty M. Shafer R. W. Bertagnolio S. Rinke de Wit T. F. (2019). Curbing the rise of HIV drug resistance in low-income and middle-income countries: The role of dolutegravir-containing regimens. The Lancet Infectious Diseases 19(7) e246\u2013e252. https:\/\/doi.org\/10.1016\/S1473-3099(18)30710-2","DOI":"10.1016\/S1473-3099(18)30710-2"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Jacobs T. G. Waalewijn H. Houlden L. Bollen P. D. J. Nanduudu A. Nambi E. . . . Colbers A. (2024). Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients. British Journal of Clinical Pharmacology 90(11) 2947\u20132952. https:\/\/doi.org\/10.1111\/bcp.16238","DOI":"10.1111\/bcp.16238"},{"key":"e_1_3_3_17_1","unstructured":"Jos\u00e9 A. L. P. (2019). National Strategic Plan for HIV Response in Honduras 2020 to 2024: Extension-of-PENSIDA-IV."},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"Kalungwe M. Mbalinda S. N. Karonga T. Simwanza N. R. Mumba Mtambo C. M. Nyashanu M. (2022). Exploring barriers to antiretroviral therapy adherence among pregnant women: A scoping literature review. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics 159(2) 343\u2013350. https:\/\/doi.org\/10.1002\/ijgo.14130","DOI":"10.1002\/ijgo.14130"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Kim A. A. Morales S. Lorenzana de Rivera I. Paredes M. Juarez S. Alvarez B. Liu X. Parekh B. Monterroso E. Paz-Bailey G. (2013). Short communication: HIV incidence among vulnerable populations in Honduras: Results from an integrated behavioral and biological survey among female sex workers men who have sex with men and Garifuna in Honduras 2006. AIDS Research and Human Retroviruses 29(3) 516\u2013519. https:\/\/doi.org\/10.1089\/AID.2012.0032","DOI":"10.1089\/aid.2012.0032"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Majula R. T. Mweya C. N. (2024). Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya Tanzania. AIDS Research and Therapy 21(1) 98. https:\/\/doi.org\/10.1186\/s12981-024-00662-z","DOI":"10.1186\/s12981-024-00662-z"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"McAllister J. W. Towns J. M. Mcnulty A. Pierce A. B. Foster R. Richardson R. Carr A. (2017). Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men. AIDS 31(9) 1291\u20131295. https:\/\/doi.org\/10.1097\/QAD.0000000000001447","DOI":"10.1097\/QAD.0000000000001447"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Ombajo L. A. Penner J. Nkuranga J. Mecha J. Mburu M. Odhiambo C. Ndinya F. Aksam R. Njenga R. Wahome S. Muiruri P. Eshiwani S. Kimani M. Ngugi C. Pozniak A. (2023). Second-line switch to dolutegravir for treatment of HIV infection. The New England Journal of Medicine 388(25) 2349\u20132359. https:\/\/doi.org\/10.1056\/NEJMoa2210005","DOI":"10.1056\/NEJMoa2210005"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Paton N. I. Musaazi J. Kityo C. Walimbwa S. Hoppe A. Balyegisawa A. Kaimal A. Mirembe G. Tukamushabe P. Ategeka G. Hakim J. Mugerwa H. Siika A. Asienzo J. Castelnuovo B. Kiragga A. Kambugu A. (2021). Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to Treat HIV. The New England Journal of Medicine 385(4) 330\u2013341. https:\/\/doi.org\/10.1056\/NEJMoa2101609","DOI":"10.1056\/NEJMoa2101609"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Paz-Bailey G. Isern Fernandez V. Morales Miranda S. Jacobson J. O. Mendoza S. Paredes M. A. Danaval D. C. Mabey D. Monterroso E. (2012). Unsafe sexual behaviors among HIV-positive men and women in Honduras: The role of discrimination condom access and gender. Sexually Transmitted Diseases 39(1) 35\u201341. https:\/\/doi.org\/10.1097\/OLQ.0b013e318231cf2d","DOI":"10.1097\/OLQ.0b013e318231cf2d"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Paz-Bailey G. Morales-Miranda S. Jacobson J. O. Gupta S. K. Sabin K. Mendoza S. Paredes M. Alvarez B. Monterroso E. (2009). High rates of STD and sexual risk behaviors among Gar\u00edfunas in Honduras. Journal of Acquired Immune Deficiency Syndromes 51(Suppl. 1) S26\u2013S34. https:\/\/doi.org\/10.1097\/QAI.0b013e3181a2647b","DOI":"10.1097\/QAI.0b013e3181a2647b"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Schneider S. Blick G. Burke C. Ward D. Benson P. Felizarta F. Green D. Donovan C. Harper G. Merrill D. Metzner A. A. Mycock K. Wallis H. Patarroyo J. Brogan A. P. Oglesby A. (2024). Two-drug regimens Dolutegravir\/Lamivudine and Dolutegravir\/Rilpivirine are effective with few discontinuations in US real-world settings: Results from the TANDEM Study. Infectious Diseases and Therapy 13(4) 891\u2013906. https:\/\/doi.org\/10.1007\/s40121-024-00961-y","DOI":"10.1007\/s40121-024-00961-y"},{"key":"e_1_3_3_27_1","unstructured":"SESAL (2018). Final Report Survey of HIV resistaance to antiretroviral medicines. https:\/\/digi.usac.edu.gt\/bvsalud\/documentos\/ligcsa\/otros\/INFORME_VIH_HONDURAS.pdf"},{"key":"e_1_3_3_28_1","unstructured":"SESAL (2023). Manual of comprehensive care for adults and adolescents with the human immunodeficiency virus."},{"key":"e_1_3_3_29_1","unstructured":"SESAL (2022). Guidelines for the provision of differentiated services to improve care and access to antiretroviral treatment. . . https:\/\/honduras.bvsalud.org\/wp-content\/uploads\/2024\/04\/lineamientos-de-prestacion-de-servicios-diferenciados-para-mejorar-la-atencion-y-acceso-al-tratamiento-antirretroviral-de-las-personas-con-vih.pdf"},{"key":"e_1_3_3_30_1","unstructured":"UNAIDS. (2023). Global HIV & AIDS statistics \u2014 Fact sheet. https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"e_1_3_3_31_1","doi-asserted-by":"crossref","unstructured":"Vitoria M. Hill A. Ford N. Doherty M. Clayden P. Venter F. Ripin D. Flexner C. Domanico P. L. (2018). The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: What are the issues? AIDS 32(12) 1551\u20131561. https:\/\/doi.org\/10.1097\/QAD.0000000000001845","DOI":"10.1097\/QAD.0000000000001845"},{"key":"e_1_3_3_32_1","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. (2021). HIV drug resistance report: Technical report.","journal-title":"HIV drug resistance report: Technical report"},{"key":"e_1_3_3_33_1","doi-asserted-by":"crossref","unstructured":"Zaniewski E. Skrivankova V. W. Brazier E. Avihingsanon A. Wagner Cardoso S. Cesar C. Cesar C. Chenal H. Crabtree-Ram\u00edrez B. E. Ditangco R. A. Ebasone P. V. Eley B. Euvrard J. G. Fatti G. Huwa J. M. Lelo P. Machado D. M. Messou E. K. Minga A. K. Muleebwa J. . . . Ballif M. (2024). Transition to dolutegravir-based ART in 35 low- and middle-income countries: A global survey of HIV care clinics. AIDS 38(15) 2073\u20132085. https:\/\/doi.org\/10.1097\/QAD.0000000000004007","DOI":"10.1097\/QAD.0000000000004007"}],"container-title":["Health Education &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10901981251411221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10901981251411221","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10901981251411221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:17:45Z","timestamp":1789791465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10901981251411221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10901981251411221"],"URL":"https:\/\/doi.org\/10.1177\/10901981251411221","relation":{},"ISSN":["1090-1981","1552-6127"],"issn-type":[{"value":"1090-1981","type":"print"},{"value":"1552-6127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]}}}